Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma by Krieger, Sophie et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Relevance of cyclin D1b expression and CCND1 polymorphism in 
the pathogenesis of multiple myeloma and mantle cell lymphoma
Sophie Krieger1, Juliette Gauduchon1, Mikel Roussel1, Xavier Troussard1,2 and 
Brigitte Sola*1
Address: 1Laboratoire de Biologie Moléculaire et Cellulaire de la Signalisation, EA 3919, Université de Caen, France and 2Laboratoire 
d'Hématologie, CHU Côte de Nacre, Caen, France
Email: Sophie Krieger - s.krieger@baclesse.fr; Juliette Gauduchon - shejaan@hotmail.com; Mikel Roussel - Mikael.ROUSSEL@chu-rennes.fr; 
Xavier Troussard - troussard-x@chu-caen.fr; Brigitte Sola* - brigitte.sola@unicaen.fr
* Corresponding author    
Abstract
Background:  The  CCND1  gene generates two mRNAs (cyclin D1a and D1b) through an
alternative splicing at the site of a common A/G polymorphism. Cyclin D1a and b proteins differ in
their C-terminus, a region involved in protein degradation and sub-cellular localization. Recent data
have suggested that cyclin D1b could be a nuclear oncogene. The presence of cyclin D1b mRNA
and protein has been studied in two hemopathies in which cyclin D1 could be present: multiple
myeloma (MM) and mantle cell lymphoma (MCL). The A/G polymorphism of CCND1 has also been
verified in a series of patients.
Methods: The expression of cyclin D1 mRNA isoforms has been studied by real-time quantitative
PCR; protein isoforms expression, localization and degradation by western blotting. The CCND1
polymorphism was analyzed after sequencing genomic DNA.
Results: Cyclin D1 mRNA isoforms a and b were expressed in mantle cell lymphoma (MCL) and
multiple myeloma (MM). Cyclin D1b proteins were present in MCL, rarely in MM. Importantly,
both protein isoforms localized the nuclear and cytoplasmic compartments. They displayed the
same short half-life. Thus, the two properties of cyclin D1b recognized as necessary for its
transforming activity are missing in MCL. Moreover, CCND1 polymorphism at the exon/intron
boundary had no influence on splicing regulation in MCL cells.
Conclusion: Our results support the notion that cyclin D1b is not crucial for the pathogenesis of
MCL and MM.
Background
Cyclin D1 is a critical regulator of the cell cycle and tran-
scriptional processes. Overexpression or overactivity of
cyclin D1 is common in human cancers. Cyclin D1 is also
expressed in lymphoid tumors such as mantle cell lym-
phoma (MCL) and multiple myeloma (MM). The expres-
sion of cyclin D1 in B-cells in which the protein is
physiologically absent, is supposed to be causal in the
transformation process. In MCL, CCND1 (encoding cyclin
D1) is activated by the t(11;14)(q13;q32) in almost 100%
of cases [1]. In multiple myeloma (MM), cyclin D1 is
expressed in 45–50% of samples but the
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t(11;14)(q13;q32) is only present in 15% of them [2]. The
human CCND1 gene encodes two mRNAs species result-
ing from an alternative splicing: form a [3] and form b
generated by the absence of splicing at the exon 4/intron
4 boundary [4]. Cyclin D1 protein isoforms differ in the
last 55 amino acids of the carboxy-terminus. Cyclin D1a
and D1b proteins possess the cyclin box necessary for cyc-
lin-dependent kinase (CDK) binding and enzymatic activ-
ity. But the PEST destruction box as well as Thr286, the
phosphorylation site of glycogen synthase kinase-3β
which promotes the nuclear export of cyclin D1 and its
turn-over, are missing in form b [5,6]. Recently, it has
been shown that cyclin D1 isoforms could display func-
tional differences and importantly that only cyclin D1b
facilitates transformation in fibroblasts [7-9]. Considering
this putative role in tumorigenesis, we have studied cyclin
D1b expression in MCL and MM samples. A common A/
G polymorphism described as a modulator of cancer risk
is thought to regulate the production of cyclin D1b [4].
We have also analyzed this relationship in MCL samples.
Methods
MCL and MM patients and cell lines
Patients with MCL or MM were diagnosed according to
criteria from the World Health Organization classification
in our institution (CHU Côte de Nacre, Caen, France);
their clinical features are presented in the Additional file
1. Signed informed consent was obtained from all
patients before all procedures as required by the institu-
tional review board. Peripheral blood or bone marrow
samples were obtained at diagnosis. Mononuclear cells
were isolated by centrifugation over a Ficoll-Hypaque
layer. CD19+ cells from 10 MCL patients were then puri-
fied (>90%) using a MACS microbeads system (Miltenyi
Biotechnology). CD138+ cells from 6 MM patients were
purified with the same system (purity >85%). JeKo-1,
NCEB-1, HBL-2 and GRANTA-519 are MCL cell lines. Kar-
pas 620, U266, NCI-H929, RPMI 8226, OPM-2 are MM
cell lines. As previously reported by us, they all expressed
cyclin D1 except OPM-2. Cell lines were maintained in
RPMI 1640 medium supplemented with 2 mM L-
glutamine, 10% heat-inactivated fetal calf serum and anti-
biotics.
Real-time quantitative RT-PCR
Total RNA was isolated from purified MCL and MM cells
and cell lines with the RNeasy Micro Kit (QIAGEN S.A.)
and reverse-transcribed with the 1st Strand cDNA Synthe-
sis kit (Roche). Real-time quantitative RT-PCR was per-
formed on an ABI PRISM 7700 Sequence Detector with
the SYBR® Green PCR Master mix (Applied Biosystems).
Primers were designed with the ABI PRISM Primer
Express® software; their sequences are presented in Table
1. For MCL and MM samples, RT-PCR amplifications were
performed in a final volume of 15 μl containing PCR mas-
ter mix, 5 ng of cDNA equivalents and primers (300 nM
each for 18S rRNA, 400 nM for cyclin D1a and 800 nM for
cyclin D1b). As negative control, real-time PCR was per-
formed with purified non reverse-transcribed RNA of each
sample. Expression of cyclin D1 isoforms compared to
18S rRNA was evaluated with the comparative threshold
method (Ct). Each experiment was done in triplicate, trip-
licate values were averaged and averaged Ct values for 18S
rRNA were subtracted from each value to give the ΔCt.
U266 and JeKo-1 cells expressing high levels of both cyc-
lin D1a and D1b mRNA were chosen as calibrators for
MM and MCL cells, respectively. ΔCt obtained from U266
or JeKo-1 was subtracted from the ΔCt of each cell line to
give ΔΔCt. The relative amount of each cyclin D1 isoform
compared to the calibrator was calculated by the formula
N = 2-ΔΔCt.
Genomic DNA purification, cDNA synthesis and 
sequencing
Genomic DNA of CD19+ MCL cells was isolated with the
Wizard®  Genomic DNA (Promega). Total RNA was
extracted from purified MCL cells and reverse-transcribed
as before. Genomic DNA and cDNA were used as tem-
plates for PCR amplification using the Exon4 D1F and
Intron4 D1R primers (see sequences in Table 1). PCR-
amplified fragments encompassing the exon 4/intron 4
boundary were sequenced using the Big Dye Terminator
Table 1: Sequences and positions of primers
Primer Position Sequence
QRT D1a S 1139 (M64349)* 5'-GGA AAG CTT CAT TCT CCT TGT TG-3'
QRT D1a AS 1217 (M64349) 5'-TTC TTT TGC TTA AGT CAG AGA TGG AA-3'
QRT D1b S 294 (X88930) 5'-GCC AAT GGT CTG TGT GGT GAT-3'
QRT D1b AS 371 (X88930) 5'-ATT GGC CAC GCA CAT TGT G-3'
QRT 18S S 450 (X03205.1) 5'-CGG CTA CCA CAT CCA AGG AA-3'
QRT 18S AS 636 (X03205.1) 5'-GCT GGA ATT ACC GCG GCT-3'
Exon4 D1F 719 (M64349) 5'-ATG TGA AGT TCA TTT CCA ATC C-3'
Intron4 D1R 195 (X88930) 5'-CCA GTC AGT AAG TTC TAG GAG CAG-3'
* Accession numbers in GenBank are in brackets.BMC Cancer 2006, 6:238 http://www.biomedcentral.com/1471-2407/6/238
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Sequencing kit (Applied Biosystems). Sequences were
analyzed with the ABI PRISM 310 Genetic Analyzer.
Immunoblotting
Nuclear, cytoplasmic or whole cell extracts, SDS-PAGE,
electro-transfer and immunoblotting, all are procedures
described previously [10]. The DCS-6 monoclonal anti-
cyclin D1 antibody (Ab, Pharmingen BD Biosciences
n°556070) is directed against the entire cyclin D1 mole-
cule and recognizes both isoforms; the sc-718 anti-cyclin
D1 Ab (Santa Cruz Biotechnologies) is directed against
the C-terminal part of the protein and is specific for cyclin
D1a, the R3 Ab is directed against the C-terminal part of
cyclin D1b and is specific for this isoform [7]. The R3 Ab
was a generous gift of Dr Alan J. Diehl. Reprobing blots
with anti-β-tubulin Ab (sc-9104, Santa Cruz Biotech.) or
anti-E2F1 (sc-251, Santa Cruz Biotech.) allowed us to
check protein loading and transfer. Densitometric analy-
ses were realized with a FluorSImager using the Quantity-
One software (Bio-Rad).
Results
Expression of cyclin D1 mRNA isoforms in MCL and MM 
patients and cell lines
Both spliced mRNAs have been detected by standard RT-
PCR in MCL primary cells and MM cell lines [11]. To
quantify the relative amounts of mRNA isoforms, primers
specific for each isoform were designed and real-time
quantitative RT-PCR was performed. The reliability of the
method is illustrated in Figure 1. Total RNA purified from
U266 cells was reverse-transcribed and serially diluted
and samples were then amplified using the specific prim-
ers. A linear correlation was confirmed by the plot of
input amount of RNA (X-axis) vs. Ct values (Y-axis) with
minimal deviation among duplicates or triplicates. The
efficacy of amplification was 100% for cyclin D1a and cyc-
lin D1b allowing the comparison of their relative levels.
The expression of cyclin D1 transcripts was normalized to
18S rRNA as internal standard. As expected, cyclin D1a
mRNA was detected in all MCL patients with ΔCta varying
from 8.8 to 12.9 (Table 2). In 9 out of 10 MCL patients,
we found the co-expression of isoform b with ΔCtb vary-
ing from 14.3 to 19.3. MCL patient 3 expressed only the
isoform a. Cyclin D1a was predominant over cyclin D1b
with a ratio R varying from 33 to 80 (Table 3). In MCL cell
lines, isoform levels were almost in the same range than
in primary cells (ΔCta 6.5–12.5, ΔCtb 12.7–19.7). In only
3 out of 6 MM patients, total cyclin D1 was detected in
CD138+ purified cells (data not shown); these three
patients were studied further for cyclin D1 isoform expres-
sion. As expected, in MM primary cells and cell lines, cyc-
lin D1 a and b expression was highly heterogeneous (ΔCta
10.0–18.2, ΔCtb 18.5–27.7) but perfectly correlated. They
globally expressed less cyclin D1b mRNA than MCL
(Table 2). The calculation of N illustrates the heterogene-
ity of cyclin D1a and b expression inside each series of
samples (MM vs. MCL) and the heterogeneity of cyclin
D1a vs. cyclin D1b expression for each case (see Addi-
tional file 2).
Expression, localization and stability of cyclin D1b protein 
in MCL samples
We detected the presence of both protein isoforms in MCL
samples except for patient 3 (Figure 2A) and in cell lines
(Figure 2B). The protein level of cyclin D1a (estimated by
densitometric analysis) was higher than of form b (from 2
to 15-fold). In whole cell extracts, cyclin D1b was not
detected in MM cell lines (data not shown), in good agree-
ment with previous report [11]. Since cyclin D1 isoforms
could display different sub-cellular localizations, nuclear
and cytoplasmic protein extracts were prepared from MCL
cell lines and primary cells and from MM cell lines, then
immunoblotted. In MCL cell lines and primary cells, cyc-
lin D1a (data not shown) and cyclin D1b localized both
the nuclear and the cytoplasmic compartments with the
exception of Pt 2 for which cyclin D1b was only nuclear
(Figure 3). A very faint band was also visible in both
extracts in NCI-H929 MM cells. Although not having the
nuclear export signal, cyclin D1b displays the same sub-
cellular distribution than cyclin D1a. GRANTA-519 and
JeKo-1 cell lines were treated with cycloheximide to
inhibit protein synthesis. We then monitored protein sta-
bility at the times indicated in the Figure 4. Cyclin D1b
exhibited a half-life similar to cyclin D1a in both cell lines
(indicated under each immunoblot). Both are short-lived
proteins despite the absence of PEST sequences in isoform
b.
Analysis of CCND1 polymorphism at position 9630 of 
genomic DNA and at position 870 of mRNA – Relation 
with the level of cyclin D1 forms a and b
CCND1 alternative splice could be modulated by a com-
mon G870A polymorphism within the splice donor site
[4]. Moreover, AA genotype could be associated with a
preferential expression of isoform b and a higher risk of
cancers [12]. As presented in Table 3, MCL patient 5 was
homozygous for the A allele, patient 6 homozygous for
the G allele, the other 4 were heterozygous. Each tumor
expressed either the A allele (3/6) or the G allele (3/6) but
none expressed both alleles. Moreover, cyclin D1b was
transcribed from the A or G allele and whatever the nucle-
otide at position 870, cyclin D1a was more expressed than
cyclin D1b. The A/G genotype does not influence the rel-
ative level of the two transcripts.
Discussion
Using standard RT-PCR, we found previously that cyclin
D1a and b were coexpressed in MCL patients and in MM
cell lines irrespectively of the presence of the t(11;14)
translocation [11]. We now extended this work and ana-BMC Cancer 2006, 6:238 http://www.biomedcentral.com/1471-2407/6/238
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lyzed cyclin D1 isoform expression with a real-time quan-
titative RT-PCR in MM and MCL primary cells and cell
lines.
Although cyclin D1 mRNA isoforms are always co-
expressed in MCL and in cyclin D1-expressing MM cells,
cyclin D1b protein was rarely and faintly expressed in MM
Real-time RT-PCR assay for cyclin D1a and b expression Figure 1
Real-time RT-PCR assay for cyclin D1a and b expression. Total RNA isolated from U266 MM cell line was serially 
diluted to obtain dilutions ranging from 10 to 0.625 ng. Cyclin D1a was amplified by RT-PCR using QRT D1a S and QRT D1a 
AS primers (400 nM) and cyclin D1b using QRT D1b S and QRT D1b AS primers (800 nM, Table 1). Amplifications are shown 
in logarithmic scale (left part). Threshold cycle (Ct) was plotted against quantity (ng) of RNA to obtain standard curve (right 
part). The slope of the curve is -3.32 indicating an amplification efficiency of 100%
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samples. By contrast, in MCL cells, cyclin D1b was often
present. Thus, post-transcriptional mechanisms regulate
cyclin D1b status depending on the B-cell hemopathy.
Cyclin D1a and D1b proteins exhibit the same stability. In
previous studies [7,8], in transfected models, the calcu-
lated half-lives of cyclin D isoforms were also similar and
similar to ours. Thus, endogenous and exogenous cyclin
D1 isoforms are subjected to the same post-translational
regulation. Either the PEST sequence is not strictly neces-
sary for proteolysis through the proteasome machinery
which is peculiarly active in MCL [13] or cyclin D1 can be
degraded through another motif. In the case of cell
response to stress, cyclin D1 can be degraded through its
binding to the anaphase-promoting complex and a RXXL
sequence located in the NH2-terminal part of the protein
[14]. This sequence is present in both cyclin D1 isoforms.
Such a mechanism could be activated constitutively in
MCL cells.
B-cell lymphomas can be induced in transgenic mice
expressing a cyclin D1 mutant (T286A) under the control
of Eμ enhancer [15]. This mutant displays a 5-fold longer
half-life than cyclin D1 [16] and is exclusively nuclear.
This sub-cellular localization seems to be a prerequisite to
transformation. In MCL cells, cyclin D1b localizes both
the nuclear and cytoplasmic compartments. In good
agreement, endogenous cyclin D1b appears cytoplasmic
and nuclear in oesophageal carcinomas [7] In contrast, in
transfected fibroblastic cells, cyclin D1b remains mostly
nuclear [7-9]. The simplest explanation is that the nuclear
export is subverted by an overexpression of exogenous
cyclin D1b.
Cyclin D1b is rarely and faintly expressed in MM and not
always detected in MCL ([17] and our results). Thus, the
expression of cyclin D1b is not necessary at least for the
maintenance of a tumoral phenotype. Interestingly, the
presence of a short cyclin D1 transcript (1.7 kb) lacking
the 3'-UTR region responsible for mRNA stability, has
been associated with MCL aggressiveness and a poor prog-
nosis [1]. The relationship between the alternative spliced
forms and the short mRNA has to be studied.
In MCL, CCND1 alternative splicing does not modulate
the level of transcripts b. This is consistent with results
showing that CCND1  alternative splicing depends on
sample origin [17]. Moreover, cyclin D1b is transcribed
independently of A/G genotype. This indicates that both
alleles can splice to form both transcripts. Besides A/G
polymorphism, trans-elements regulate alternative splic-
ing. In good agreement with us, Howe and Lynas also
Table 3: CCND1 polymorphism, monoallelic transcription and 
cyclin D1 mRNA level
MCL patient Position 9630 Position 870 R*
1A / G G 6 0
2A / G G 3 3
4n dn d 3 9
5A A8 0
6G G 7 8
7A / G A4 5
8A / G A3 6
Genomic DNA and total RNA were extracted from CD19+ MCL 
cells and purified. RNA was reverse-transcribed and DNA samples 
were PCR-amplified before sequencing with Exon4 D1F and Intron4 
D1R primers. Only the cyclin D1b mRNA form can be amplified with 
this couple of primers. Nucleotides at position 9630 (AP001888, 
GenBank) of genomic DNA and at position 870 of cDNA (M64349, 
GenBank) are indicated. * R, the relative ratio of cyclin D1a mRNA vs. 
cyclin D1b mRNA was calculated with the formula R = 2-(ΔCta-ΔCtb). nd, 
not determined.
Table 2: Cyclin D1a and cyclin D1b mRNA expression in MCL 
and MM samples
Sample ΔCta ΔΔCta Na ΔCtb ΔΔCtb Nb
MCL
JeKo-1* 6.5 0 1 12.7 0 1
GRANTA-519 12.5 6.0 0.0156 19.0 6.3 0.0127
HBL-2 7.8 1.3 0.4061 14.5 1.8 0.2871
NCEB-1 10.9 4.4 0.0474 19.7 7.0 0.0078
Pt 1 10.4 3.9 0.0670 19.3 6.6 0.0103
Pt 2 11.3 4.8 0.0359 16.4 6.7 0.0096
Pt 3 10.1 5.6 0.0206 nc nc nc
Pt 4 12.9 6.4 0.0118 18.2 8.5 0.0028
Pt 5 9.2 2.7 0.1539 15.5 5.8 0.0179
Pt 6 8.8 2.3 0.2030 15.0 5.3 0.0254
Pt 7 11.4 4.9 0.0335 16.9 7.2 0.0068
Pt 8 9.1 2.6 0.1650 14.3 4.6 0.0412
Pt 9 12.2 5.7 0.0192 17.0 7.3 0.0063
MM
U266* 10.0 0 1 18.8 0 1
Karpas 620 13.9 3.9 0.0670 20.8 2.0 0.2500
RPMI 8226 17.1 7.1 0.0073 23.9 5.1 0.0291
NCI-H929 15.9 5.9 0.0167 23.7 4.9 0.0335
O P M - 2 n c n cn cn c n cn c
Pt 1 12.3 2.3 0.2030 18.5 -0.3 1.2311
Pt 2 18.2 8.2 0.0034 27.7 8.9 0.0021
Pt 3 15.0 5.0 0.0312 27.1 8.3 0.0032
The quantitation of cyclin D1a and cyclin D1b mRNA compared to 
18S rRNA was done using the comparative threshold (Ct) method 
with the ABI PRISM 7000 SDS software. Triplicate experiments were 
done for each sample; for each sample the average Ct value for the 
internal standard was subtracted from the average Ct value for cyclin 
D1a or cyclin D1b to yield ΔCta and ΔCtb. ΔCt obtained from the 
calibrator cell lines (* JeKo-1 for MCL samples and U266 for MM 
samples) was subtracted from each ΔCta or ΔCtb to give the ΔΔCt. 
The relative amount of cyclin D1a and cyclin D1b compared to the 
calibrator was calculated by the formula N = 2-ΔΔCt. No cyclin D1b 
was detected in MCL patient 3 (Ctb>50); no cyclin D1a or b was 
detected in OPM-2 MM cell line (Cta>50 and Ctb>50). nc, not 
calculated; Pt, patient.BMC Cancer 2006, 6:238 http://www.biomedcentral.com/1471-2407/6/238
Page 6 of 8
(page number not for citation purposes)
showed that CCND1 polymorphism does not affect the
prognosis of MCL patients [18].
In breast, sarcoma and colon cancers, with cyclin D1 over-
expression and no chromosome 11 alterations, elevated
mRNA levels result from a trans-acting influence of both
alleles [19]. A biallelic expression is seen in MM tumors
without the t(11;14) [2]. In agreement with that observed
in MM tumors with t(11;14), only one allele is transcribed
in MCL cells, the transcribed allele is likely the structurally
altered one.
Conclusion
Although cyclin D1b mRNA is produced in the vast major-
ity of MM and MCL cells, cyclin D1b protein is not always
found and not found exclusively in the nucleus. These
data allowed us to conclude that a transforming activity of
cyclin D1b over cyclin D1a is unlikely. Moreover, our data
establish no relationship between A/G polymorphism
and cyclin D1b expression. The relevance of cyclin D1b in
MCL and MM pathologies remains elusive.
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Cyclin D1a and cyclin D1b protein expression Figure 2
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and analyzed as described in A except that we used DCS-6 anti-cyclin D1 Ab which recognizes both isoforms.
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Cyclin D1b sub-cellular localization and stability Figure 3
Cyclin D1b sub-cellular localization and stability. Nuclear and cytoplasmic extracts were prepared from cell lines and 
purified CD19+ primary cells and analyzed as described before. Blots were re-probed with anti-β-tubulin or anti-E2F1 (nuclear 
extracts, sc-251) Abs for loading controls.
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Stability of cyclin D1a and cyclin D1b isoforms Figure 4
Stability of cyclin D1a and cyclin D1b isoforms. GRANTA-519 and JeKo-1 cells were untreated (C) or treated with 
cycloheximide (50 μg/ml final concentration) for 3 h. Cells were harvested 20–180 min later and total proteins were extracted 
and analyzed as described before. A densitometric analysis was performed to quantify proteins level and to estimate proteins 
half-life. Half-lives are indicated under the blots.
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